Evidence map›Paper›PMID 41851506›Full record

Trial reportNature cancer2026

Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2

Rashmi K Murthy, Barbara J O'Brien, Donald A Berry, Akshara Singareeka-Raghavendra, Maria Gule Monroe, Jason Johnson, Jason White, Jill Schwartz-Gomez, Ariel Topletz-Erickson, Mina Lobbous and 12 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Rashmi K Murthy *University of Texas MD Anderson Cancer Center, Houston, TX, USA. rmurthy1@mdanderson.org.ORCID http://orcid.org/0000-0002-0103-4718
Barbara J O'Brien *University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Donald A BerryUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Akshara Singareeka-RaghavendraUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6425-4400
Maria Gule MonroeUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jason JohnsonUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jason WhiteUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7140-545X
Jill Schwartz-GomezUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ariel Topletz-EricksonPfizer, Inc., Bothell, WA, USA.
Mina LobbousUniversity of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, AL, USA.
Kristen RileyUniversity of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, AL, USA.ORCID http://orcid.org/0000-0001-5895-6855
Michelle MeliskoUniversity of California San Francisco, San Francisco, CA, USA.
Aki MorikawaUniversity of Michigan, Ann Arbor, MI, USA.
Sherise D FergusonUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
John F de GrootUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1454-6461
Ian E KropYale Cancer Center, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-6380-5944
Vicente ValeroUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mothaffar F RimawiBaylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0002-4284-5656
Antonio C WolffJohns Hopkins University, Baltimore, MD, USA.
Debu TripathyUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5711-2404
Nancy U LinDana-Farber Cancer Center, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2263-5413
Erica M Stringer-ReasorUniversity of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, AL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatments for leptomeningeal metastasis (LM) are limited and prognosis is poor. In this phase 2, nonrandomized, single-arm, multicenter study, we evaluated a tucatinib-trastuzumab-capecitabine regimen in patients with newly diagnosed LM and human epidermal growth factor receptor 2-positive (HER2

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesMeningeal CarcinomatosisMeningeal NeoplasmsAdultAgedCapecitabineFemaleHumansMiddle AgedOxazolesPyridinesQuinazolinesTrastuzumabCapecitabineERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesOxazolesPyridinesQuinazolinesTrastuzumabtucatinib

Identifiers

PMID41851506
PMCPMC13035468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.